3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
33
Colorectal Neoplasms
13
Neoplasms
11
Pain, Postoperative
10
Lung Neoplasms
9
Brain Neoplasms
8
Stomach Neoplasms
7
Prostatic Neoplasms
7
Pancreatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Melanoma
6
Leukemia, Myeloid, Acute
5
Ovarian Neoplasms
4
Myoma
4
Lymphoma, Non-Hodgkin
4
Leiomyoma
4
Hemorrhage
4
Head and Neck Neoplasms
4
Glioblastoma
4
Colonic Neoplasms
4
Agnosia
4
Skin Neoplasms
3
Recurrence
3
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neurotoxicity Syndromes
3
Neoplasm Metastasis
3
Nasopharyngeal Carcinoma
3
Myelodysplastic Syndromes
3
Multiple Endocrine Neoplasia Type 1
3
Interventions
human papillomavirus vaccine, L1 type 16, 18
36
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
29
Papillomavirus Vaccines
22
Vaccines
11
Human Papillomavirus Recombinant Vaccine nonavalent
11
Radiotherapy, Intensity-Modulated
7
Human Papillomavirus DNA Tests
7
Colposcopy
7
Cisplatin
7
Educational Status
6
Carboplatin
6
Blood Specimen Collection
6
Vaccines, Synthetic
5
Specimen Handling
5
Early Intervention, Educational
5
Vaginal Smears
4
Methods
4
Engerix-B
4
fludarabine
3
epigallocatechin gallate
3
artesunic acid
3
artemisinin
3
Watchful Waiting
3
Surveys and Questionnaires
3
Patient Navigation
3
Paclitaxel
3
Imiquimod
3
Hepatitis A Vaccines
3
Cyclophosphamide
3
halofantrine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Papillomavirus Infections
×
Sodium Chloride
×
Clear all
NCT04199689
2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
6,033 enrolled